Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use
The present invention provides compositions containing clopidogrel, present as a free base or a pharmaceutically acceptable salt thereof, and sulfoalkyl ether cyclodextrin (SAE-CD). The compositions can be liquid, suspension or solid compositions. They can be adapted for oral, peroral or parenteral administration. The SAE-CD serves to aid in dissolution and stabilization of the clopidogrel in aqueous media. The stability of clopidogrel against hydrolytic degradation, thermal degradation, and photolytic degradation are improved. SAE-CD provides improved results over other cyclodextrin derivatives. The SAE-CD-containing composition of clopidogrel can be provided in liquid form, solid form or as a reconstitutable powder. Both ready-to-use and concentrated liquid compositions can be prepared. The liquid composition is optionally available as a clear solution. The compositions herein can be administered perorally or parenterally and provide substantial pharmacokinetic, pharmacodynamic and/or therapeutic advantages over a tablet composition administered perorally and excluding SAE-CD.
1. A kit comprising a first pharmaceutical composition comprising SAE-CD and a second pharmaceutical composition comprising clopidogrel, wherein the SAE-CD has the structure:
wherein: n is 4, 5, or 6; R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , and R 9 are each, independently, —O— or a —O—(C 2 -C 6 alkylene)-SO 3 − group, wherein at least one of R 1 to R 9 is independently a —O—(C 2 -C 6 alkylene)-SO 3 − group; and S 1 , S 2 , S 3 , S 4 , S 5 , S 6 , S 7 , S 8 , and S 9 are each, independently, a pharmaceutically acceptable cation.
2. The kit of claim 1 , wherein the first or second pharmaceutical composition independently comprises upon each occurrence a liquid carrier.
3. The kit of claim 1 , wherein the SAE-CD has the structure:
or a pharmaceutically acceptable salt of any of the foregoing, wherein each R substituent independently is —H or —(CH 2 ) 4 —SO 3 Na, and wherein the SAE-CD has an average of between 6 and 7.1 —(CH 2 ) 4 —SO 3 Na substituents per cyclodextrin molecule.
4. A pharmaceutical kit comprising: a first chamber comprising a liquid carrier; and a second chamber comprising a solid pharmaceutical composition comprising SAE-CD and clopidogrel, wherein the SAE-CD has the structure:
wherein: n is 4, 5, or 6; R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , and R 9 are each, independently, —O— or a —O—(C 2 -C 6 alkylene)-SO 3 − group, wherein at least one of R 1 to R 9 is independently a —O—(C 2 -C 6 alkylene)-SO 3 − group; and S 1 , S 2 , S 3 , S 4 , S 5 , S 6 , S 7 , S 8 , and S 9 are each, independently, a pharmaceutically acceptable cation.
5. The kit of claim 4 , wherein the first and second chambers are integral, engaged or assembled to form a container comprising at least two chambers.
6. The kit of claim 4 , wherein the first and second chambers are separate and form separate containers.
7. The kit of claim 4 , wherein the solid pharmaceutical composition is a reconstitutable solid pharmaceutical composition comprising a preformed complex of SAE-CD and clopidogrel.
8. The kit of claim 4 , wherein the solid pharmaceutical composition comprises an admixture of SAE-CD and clopidogrel.
9. The kit of claim 4 , wherein the liquid carrier is an aqueous liquid carrier.
10. The kit of claim 9 , wherein the aqueous liquid carrier comprises water, dextrose, saline, lactated Ringer's solution, buffer, a pharmaceutically acceptable aqueous liquid vehicle or a combination thereof.
11. The kit of claim 4 , wherein the liquid carrier is an aqueous liquid carrier and the solid pharmaceutical composition comprises an admixture of SAE-CD and clopidogrel.
12. The kit of claim 11 , wherein aqueous liquid carrier and the solid pharmaceutical composition form a composition with a pH of 3.5 or higher, and a molar ratio of the SAE-CD to the clopidogrel is 6:1 to 40:1.
13. The kit of claim 11 , wherein aqueous liquid carrier and the solid pharmaceutical composition form a composition with a pH of 5.5 to 8, and a molar ratio of the SAE-CD to the clopidogrel is 6.5:1 to 12.5:1.
14. The kit of claim 4 , wherein the SAE-CD has the structure:
or a pharmaceutically acceptable salt of any of the foregoing, wherein each R substituent is independently —H or —(CH 2 ) 4 —SO 3 Na, and wherein the SAE-CD has an average of between 6 and 7.1 —(CH 2 ) 4 —SO 3 Na substituents per cyclodextrin molecule.